Tyra Biosciences
TYRA
45 hedge funds and large institutions have $494M invested in Tyra Biosciences in 2021 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 9 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
211% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 9
73% more funds holding
Funds holding: 26 → 45 (+19)
23.92% more ownership
Funds ownership: 61.31% → 85.23% (+24%)
8% more capital invested
Capital invested by funds: $457M → $494M (+$37.4M)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$31M |
| 2 |
BlackRock
New York
|
+$11.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.3M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.1M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$3.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$11M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$10.5M |
| 3 |
Jennison Associates
New York
|
-$8.24M |
| 4 |
PA
Perceptive Advisors
New York
|
-$6.24M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.57M |
TYRA Hedge Fund Activity: Q4 2021 in Review
45 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Tyra Biosciences (TYRA) for Q4 2021, worth a combined $494M — up 8.2% from $457M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new TYRA positions and 9 closed out — a net gain of 19 holders — while 7 added to existing stakes and 7 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $31M. The largest seller was Deerfield Management, exiting entirely with an estimated $11M sold.
- 45 institutional investors held Tyra Biosciences (TYRA) as of Q4 2021, up from 26 in Q3 2021.
- Funds reported $494M of Tyra Biosciences stock for Q4 2021, up 8.2% quarter-over-quarter.
- 28 funds opened new Tyra Biosciences positions in Q4 2021 and 9 closed out, a net change of +19 holders.
- The largest Tyra Biosciences buyer in Q4 2021 was Fidelity Investments, an estimated $31M added.
- The largest Tyra Biosciences seller in Q4 2021 was Deerfield Management, an estimated $11M sold.
Based on aggregated 13F filings for Q4 2021.